Ulrich Bothe

USPTO Granted Patents = 23 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 17 (Patent Applications = 21)

Average Co-Inventor Count = 7.6

ph-index = 5

Forward Citations = 66(Granted Patents)

Location History:

Jena, DE (2007)
Berlin, DE (2007 - 2024)

Company Filing History:

13 out of 378

Bayer Pharma Aktiengesellschaft

patents

3 out of 192

Bayer Schering Pharma Ag

patents

3 out of 1,384

Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

patents

6. 1 out of 2

Bayer Pharma Aktiengessellschaft

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12459916 - Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals (2025-11-04),

2. 12006304 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

3. 12006303 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

4. 11992481 - Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases (2024-05-28),

5. 10793545 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2020-10-06),

6. 10730856 - Benzimidazole derivatives as EP4 ligands (2020-08-04),

7. 10435396 - 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs (2019-10-08),

8. 10308634 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2019-06-04),

9. 9951086 - Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments (2018-04-24),

10. 9714266 - Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) (2017-07-25),

11. 9512169 - 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments (2016-12-06),

12. 9487554 - Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments (2016-11-08),

13. 8642611 - Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2014-02-04),

14. 8492570 - 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action (2013-07-23),

15. 8163739 - 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals (2012-04-24),

Title: Ulrich Bothe: Innovator in Pharmaceutical Chemistry

Introduction

Ulrich Bothe, based in Berlin, Germany, is a distinguished inventor known for his groundbreaking work in pharmaceutical chemistry. With a portfolio of 22 patents, he has made significant contributions to the development of novel therapies, particularly for complex diseases.

Latest Patents

Among Ulrich Bothe's most recent innovations are his patents related to substituted indazoles. These inventions encompass methods for their production, pharmaceutical preparations that include these compounds, and their use in drug formulation. The focus of these patents is on treatments for various diseases, notably endometriosis and its associated symptoms, as well as conditions such as lymphoma, rheumatoid arthritis, lupus erythematosus, and multiple sclerosis. His innovative approaches aim to provide effective therapeutics for patients suffering from chronic illnesses.

Career Highlights

Ulrich Bothe has spent a significant portion of his career at Bayer Pharma and Bayer Schering Pharma, where he contributed to numerous projects that highlight his expertise in medicinal chemistry. His work has played a pivotal role in advancing the pharmaceutical industry, particularly in developing medications that target a range of serious health issues.

Collaborations

Throughout his career, Ulrich has worked alongside esteemed colleagues such as Ulf Bömer and Holger Siebeneicher. These collaborations have enriched his research and helped propel innovations from concept to application in the medical field.

Conclusion

Ulrich Bothe's contributions to the realm of pharmaceutical inventions through his patents on substituted indazoles demonstrate his commitment to enhancing patient care. His inventive spirit, combined with his collaborative efforts, continues to influence the development of effective therapies for many challenging diseases.

This text is generated by artificial intelligence and may not be accurate.